Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRCT NASDAQ:INCR NASDAQ:TRAW NASDAQ:XLO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRCTDirect Digital$3.03+4.1%$3.24$2.17▼$172.70$2.25M5.3381,715 shs50,529 shsINCRInterCure$0.87+0.3%$0.86$0.68▼$1.77$47.79M1.3834,845 shs494,487 shsTRAWTraws Pharma$1.28+0.8%$1.49$1.00▼$3.27$13M1.45555,907 shs255,432 shsXLOXilio Therapeutics$8.31+4.0%$8.23$6.47▼$12.74$54.64M-0.1225,310 shs12,327 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRCTDirect Digital+4.12%+4.84%-16.07%-22.70%-97.48%INCRInterCure+0.34%-14.31%+6.59%+10.63%-43.06%TRAWTraws Pharma+0.79%-6.57%-25.58%-36.00%-30.43%XLOXilio Therapeutics+4.01%+7.92%+7.09%+16.09%-14.35%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRCTDirect Digital$3.03+4.1%$3.24$2.17▼$172.70$2.25M5.3381,715 shs50,529 shsINCRInterCure$0.87+0.3%$0.86$0.68▼$1.77$47.79M1.3834,845 shs494,487 shsTRAWTraws Pharma$1.28+0.8%$1.49$1.00▼$3.27$13M1.45555,907 shs255,432 shsXLOXilio Therapeutics$8.31+4.0%$8.23$6.47▼$12.74$54.64M-0.1225,310 shs12,327 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRCTDirect Digital+4.12%+4.84%-16.07%-22.70%-97.48%INCRInterCure+0.34%-14.31%+6.59%+10.63%-43.06%TRAWTraws Pharma+0.79%-6.57%-25.58%-36.00%-30.43%XLOXilio Therapeutics+4.01%+7.92%+7.09%+16.09%-14.35%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRCTDirect Digital 1.50ReduceN/AN/AINCRInterCure 1.00SellN/AN/ATRAWTraws Pharma 2.50Moderate Buy$8.00525.00% UpsideXLOXilio Therapeutics 2.50Moderate Buy$28.00236.94% UpsideCurrent Analyst Ratings BreakdownLatest TRAW, DRCT, XLO, and INCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2026TRAWTraws Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (E+)5/26/2026XLOXilio Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/20/2026TRAWTraws Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.005/15/2026TRAWTraws Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/8/2026XLOXilio Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/1/2026TRAWTraws Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D+)3/27/2026INCRInterCure Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRCTDirect Digital$34.69M0.06N/AN/A($18.82) per share-0.16INCRInterCure$78.47M0.61N/AN/A$2.11 per share0.41TRAWTraws Pharma$2.79M4.66$0.76 per share1.68($0.07) per share-18.29XLOXilio Therapeutics$43.77M1.25N/AN/A$7.31 per share1.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRCTDirect Digital-$18.95M-$201.62N/AN/AN/A-65.75%N/A-59.57%8/4/2026 (Estimated)INCRInterCure-$10.37M$0.03N/AN/AN/AN/AN/AN/AN/ATRAWTraws Pharma$9.17M-$1.69N/AN/AN/AN/A-913.18%-133.88%8/13/2026 (Estimated)XLOXilio Therapeutics-$35.04M-$3.55N/AN/AN/A-58.52%-151.42%-27.61%8/13/2026 (Estimated)Latest TRAW, DRCT, XLO, and INCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q4 2025TRAWTraws Pharma-$0.92-$0.53+$0.39-$0.53$2.72 millionN/A5/12/2026Q1 2026XLOXilio Therapeutics-$0.66-$0.58+$0.08-$0.58$8.52 million$12.65 million5/11/2026Q4 2025DRCTDirect Digital-$7.74-$7.25+$0.49-$10.32$6.82 million$6.68 million4/30/2026Q4 2025INCRInterCureN/A-$0.10N/A-$0.10N/A$23.15 million4/15/2026Q4 2025TRAWTraws Pharma-$1.2238-$0.71+$0.5138-$0.71$0.06 millionN/A3/23/2026Q4 2025XLOXilio Therapeutics-$1.68-$0.85+$0.83$0.81$10.90 million$13.69 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDRCTDirect DigitalN/AN/AN/AN/AN/AINCRInterCureN/AN/AN/AN/AN/ATRAWTraws PharmaN/AN/AN/AN/AN/AXLOXilio TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRCTDirect DigitalN/A0.160.16INCRInterCure0.201.480.97TRAWTraws PharmaN/A0.430.43XLOXilio TherapeuticsN/A3.593.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRCTDirect Digital4.02%INCRInterCure8.34%TRAWTraws Pharma7.95%XLOXilio Therapeutics54.29%Insider OwnershipCompanyInsider OwnershipDRCTDirect Digital25.57%INCRInterCure0.24%TRAWTraws Pharma7.57%XLOXilio Therapeutics7.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRCTDirect Digital60740,000553,000Not OptionableINCRInterCure35054.68 million54.55 millionOptionableTRAWTraws Pharma1710.16 million9.39 millionNo DataXLOXilio Therapeutics706.58 million6.09 millionNot OptionableTRAW, DRCT, XLO, and INCR HeadlinesRecent News About These CompaniesXilio Therapeutics (NASDAQ:XLO) Shares Down 0.3% - What's Next?June 9, 2026 | americanbankingnews.comXilio Therapeutics IncJune 2, 2026 | edition.cnn.comCancer Stocks That Are Advancing the Future of Oncology CareMay 18, 2026 | zacks.comXilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue EstimatesMay 12, 2026 | zacks.comXilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business UpdatesMay 12, 2026 | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 7, 2026 | globenewswire.comXilio Therapeutics (XLO) price target decreased by 28.57% to 20.40April 28, 2026 | msn.comXilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2April 17, 2026 | globenewswire.comXilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of DirectorsApril 16, 2026 | markets.businessinsider.comXilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D.April 16, 2026 | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 3, 2026 | globenewswire.comXilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?April 1, 2026 | zacks.comXilio Therapeutics (XLO) price target increased by 1,300.00% to 28.56March 28, 2026 | msn.comCancer Stocks to Buy as Innovation Reshapes Global Oncology MarketMarch 26, 2026 | zacks.comXilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial ResultsMarch 23, 2026 | globenewswire.comXilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual MeetingMarch 17, 2026 | globenewswire.comXilio Therapeutics Announces 1-for-14 Reverse Stock SplitMarch 12, 2026 | globenewswire.comXilio Therapeutics to Present at the Leerink Partners Global Healthcare ConferenceMarch 2, 2026 | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 2, 2026 | globenewswire.comXilio Therapeutics Shareholders Approve Flexible Reverse Stock SplitFebruary 24, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTRAW, DRCT, XLO, and INCR Company DescriptionsDirect Digital NASDAQ:DRCT$3.03 +0.12 (+4.12%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$2.96 -0.07 (-2.31%) As of 06/12/2026 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Direct Digital Holdings, Inc. operates as an end-to-end full-service programmatic advertising platform. The company's platform primarily focuses on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy- and sell-side of the digital advertising ecosystem. It serves various industry verticals, such as travel, healthcare, education, financial services, consumer products, and other sectors with a focus on small and mid-sized businesses. The company was founded in 2018 and is headquartered in Houston, Texas.InterCure NASDAQ:INCR$0.87 +0.00 (+0.34%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$0.87 0.00 (-0.23%) As of 06/12/2026 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.Traws Pharma NASDAQ:TRAW$1.28 +0.01 (+0.79%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$0.96 -0.32 (-25.31%) As of 06/12/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.Xilio Therapeutics NASDAQ:XLO$8.31 +0.32 (+4.01%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$8.47 +0.16 (+1.97%) As of 06/12/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears This Energy Stock Has Quietly Soared 130% in a Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
